Pharmacokinetic study of oral fosinopril in healthy Chinese volunteers

Yaoxue Xuebao

Volumn 35, Issue 8, 2000, Pages 601-604

  Li, Wen Yan ^a   Ji, Jia Zhu ^a   Guo, Ji Fen ^b   Zhang, Yi Fan ^b   Zhong, Da Fang ^b  

^a Zhabei District Central Hospital   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Fosinopril; Fosinoprilat; LC MS MS; Pharmacokinetics

Indexed keywords

EID: 0041723007     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Deforrest JM, Waldron TL, Harvey CM, et al. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and pre-clinical in vivo pharmacology [J]. J Cardiovasc Pharmacol, 1989, 14 (5):730-736.
2. Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects[J]. Br J Clin Pharmacol, 1988,25(1):9-15.
3. Kostis JB, Garland WT, Delaney C, et al. Fosinopril: Pharmacokinetics and pharmacodynamics in congestive heart failure[J]. Clin Pharmacol Ther, 1995,58(6):660 -665.
4. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies[J]. J Pharm Sci, 1992,81(3):309-312.
5. Verweij AMA, Hordijk ML, Lipman PJL. Liquid chromatographic-thermospray tandem mass spectrometric quantitative analysis of some drugs with hypnotic, sedative and tranquillising properties in whole blood [J]. J Chromatogr B, 1996,686(1):27-34.
6. Duchin KL, Waclawski AP, Tu JI, et al. Pharmacokinetics, safety and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects[J]. J Clin Pharmacol, 1991,31(1):58-64.
7. Hui KK, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function[J]. Clin Pharmacol Ther, 1991,49(4):457-467.